Advanced search
Start date
Betweenand
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Ten years of iPSC: clinical potential and advances in vitro hematopoietic differentiation

Full text
Author(s):
Martins Fernandes Paes, Barbara Cristina ; Moco, Pablo Diego ; Pereira, Cristiano Goncalves ; Porto, Geciane Silveira ; de Sousa Russo, Elisa Maria ; Junqueira Reis, Luiza Cunha ; Covas, Dimas Tadeu ; Picanco-Castro, Virginia
Total Authors: 8
Document type: Review article
Source: CELL BIOLOGY AND TOXICOLOGY; v. 33, n. 3, p. 233-250, MAY 2017.
Web of Science Citations: 6
Abstract

Ten years have passed since the first publication announcing the generation of induced pluripotent stem cells (iPSCs). Issues related to ethics, immune rejection, and cell availability seemed to be solved following this breakthrough. The development of iPSC technology allows advances in in vitro cell differentiation for cell therapy purpose and other clinical applications. This review provides a perspective on the iPSC potential for cell therapies, particularly for hematological applications. We discuss the advances in in vitro hematopoietic differentiation, the possibilities to employ iPSC in hematology studies, and their potential clinical application in hematologic diseases. The generation of red blood cells and functional T cells and the genome editing technology applied to mutation correction are also covered. We highlight some of the requirements and obstacles to be overcome before translating these cells from research to the clinic, for instance, iPSC variability, genotoxicity, the differentiation process, and engraftment. Also, we evaluate the patent landscape and compile the clinical trials in the field of pluripotent stem cells. Currently, we know much more about iPSC than in 2006, but there are still challenges that must be solved. A greater understanding of molecular mechanisms underlying the generation of hematopoietic stem cells is necessary to produce suitable and transplantable hematopoietic stem progenitor cells from iPSC. (AU)

FAPESP's process: 16/08373-9 - Obtaintion of erythrocytes from induced pluripotent stem cells in feeder-free culture with xeno-free culture medium
Grantee:Bárbara Cristina Martins Fernandes Paes
Support type: Scholarships in Brazil - Master
FAPESP's process: 14/22500-8 - Identification of patent-based technological trends in red biotechnology
Grantee:Cristiano Gonçalves Pereira
Support type: Scholarships in Brazil - Post-Doctorate
FAPESP's process: 16/08374-5 - Modification of t cells with anti-CD19 chimeric antigen receptor
Grantee:Pablo Diego Moço
Support type: Scholarships in Brazil - Master
FAPESP's process: 13/08135-2 - CTC - Center for Cell-Based Therapy
Grantee:Dimas Tadeu Covas
Support type: Research Grants - Research, Innovation and Dissemination Centers - RIDC